We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mini-Gene Therapy for Cystic Fibrosis

By Biotechdaily staff writers
Posted on 21 May 2002
Shortened versions of the normal cystic fibrosis transmembrane regulator (CFTR) can function like normal, full-length protein in experimental models of cystic fibrosis (CF) disease, according to researchers at the University of Iowa (UI, Iowa City, USA; www.uiowa.edu). More...
This finding may lead to strategies that could make gene therapy for CF a reality.

Despite the advantages of an adeno-associated virus (AAV) as a vector for gene therapy for CF, AAV is too small to accommodate the normal CFTR gene. The researchers made a series of mini-CFTR genes that produce shortened protein in airway cells by deleting parts of the CFTR protein from a region called the R domain. Two model CF cell systems were used to test the ability of the shortened proteins to act like normal, full-length CFTR in airway cells. The experimental models are designed to mimic airway cells in humans with CF. In both models, each mini-gene made protein with all the properties and function of the normal full-length protein. Additional studies are needed to generate an AAV vector that could prove useful in CF gene therapy.

"We proved that we could actually take out a fairly significant part of the domain without affecting the protein's ability to transport chloride ions and without affecting its ability to get to the right place in the cell to start working,” said Lynda S. Ostedgaard, Ph.D., UI associate research scientist in internal medicine and lead author of the study.

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
All-in-One Molecular System
AIO M160
New
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.